Vor Biopharma presented clinical and commercial details for telitacicept at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, outlining a dual-path strategy that the company says gives it a leading position in the myasthenia gravis market.
Telitacicept, marketed as Taly, is a dual BAFF/APRIL inhibitor built on the TACI framework that maintains a 2-to-1 potency ratio of BAFF to APRIL, mirroring native TACI. The drug covers IgG, IgA, and IgM antibodies. Yale research cited by Vor found that roughly one-third of myasthenia gravis patients carry IgA and IgM antibodies linked to non-response to FcRn inhibitors such as argenx's efgartigimod.
In Vor's studies, 100% of patients achieved at least a 2-point response on the MG-ADL scale, which the company described as the strongest data set seen to date in the indication. The current dosing regimen is 240 mg per week delivered via two subcutaneous injections of 1.5 mL each; Vor plans to transition to a single prefilled syringe for weekly use and add an auto-injector option.
Safety is being drawn from approximately 3,000 patients across randomized controlled trials spanning multiple indications, along with tens of thousands of patients treated in China. An ocular myasthenia gravis trial is enrolling MGFA Class I patients in a 24-week randomized study with an open-label extension of at least one year. Data from that trial is due to be presented at the AANEM conference next week.
On the commercial side, Vor estimates a $3 billion addressable opportunity in the second-line segment alone for myasthenia gravis. The broader MG biologics market has been growing at roughly 60% annually, but only about 20% of MG patients currently receive biologic therapy, compared to approximately 75% of multiple sclerosis patients. Dallan Murray, Vor's chief commercial officer, said the company believes it has best-in-disease data in its beachhead indication.
"While it's an orphan market, there's no one-time gene therapies," Murray said. "If there's a better profile of a drug coming in, the physician and patient community will move to that new option." He noted the first-mover advantage is particularly large in an orphan market driven by a small number of neuromuscular key opinion leaders.
Vor claimed a development lead of approximately three years over Vertex Pharmaceuticals' povetacicept, which is guided to disclose Phase II data in the first half of next year.
For UPLIZNA, the company noted it accounts for roughly 50% of its usage in first-line patients, and the drug is associated with about a 9% total immunoglobulin reduction.
Shares of Vor Biopharma closed at $19.87, down 2.130 or 9.68%, on the day of the forum. The stock has surged 73% over the past six months and 68% year-to-date, against a beta of 1.72. The company carries a market capitalization of $1.19 billion.
